GLENMARK SPECLT
GenericsGLENMARK SPECLT is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Dermatology. Key products include RYALTRIS.
GLENMARK SPECLT's Key Drugs
GLENMARK SPECLT's core commercial portfolio centers on RYALTRIS, HAILEY FE 1.5/30, HAILEY 1.5/30, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
GLENMARK SPECLT's Recent FDA Approvals
GLENMARK SPECLT secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
GLENMARK SPECLT's Therapeutic Areas
GLENMARK SPECLT's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GLENMARK SPECLT's Top Competitors
GLENMARK SPECLT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, APOTHECON, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GLENMARK SPECLT Pipeline Snapshot
Active clinical trials for GLENMARK SPECLT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RYALTRIS leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2015-06-09
- Latest
- 2026-06-08
- Applications
- 29